BRIEF-Shanghai Fosun Pharma Says Approval Received From NMPA For Clinical Trial Of CMC-2310 Oral Soluble Film

Reuters2025-04-07

April 7 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:

RECEIVED APPROVAL FROM NMPA FOR THE CLINICAL TRIAL OF CMC-2310 ORAL SOLUBLE FILM

Further company coverage: 600196.SS

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2525015392?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-07 18:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525015392","market":"nz","top_or_hot":-1,"title":"BRIEF-Shanghai Fosun Pharma Says Approval Received From NMPA For Clinical Trial Of CMC-2310 Oral Soluble Film","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Shanghai Fosun Pharma Says Approval Received From NMPA For Clinical Trial Of CMC-2310 Oral Soluble Film</title></head><body><p><span>April 7 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun Pharmaceutical Group Co Ltd</a> <span>600196.SS</span>:</p><ul><li><p>RECEIVED APPROVAL FROM NMPA FOR THE CLINICAL TRIAL OF CMC-2310 ORAL SOLUBLE FILM</p></li></ul><p>Further company coverage: <span>600196.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Shanghai Fosun Pharma Says Approval Received From NMPA For Clinical Trial Of CMC-2310 Oral Soluble Film</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Shanghai Fosun Pharma Says Approval Received From NMPA For Clinical Trial Of CMC-2310 Oral Soluble Film\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-07 18:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Shanghai Fosun Pharma Says Approval Received From NMPA For Clinical Trial Of CMC-2310 Oral Soluble Film</title></head><body><p><span>April 7 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun Pharmaceutical Group Co Ltd</a> <span>600196.SS</span>:</p><ul><li><p>RECEIVED APPROVAL FROM NMPA FOR THE CLINICAL TRIAL OF CMC-2310 ORAL SOLUBLE FILM</p></li></ul><p>Further company coverage: <span>600196.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL023:1","article_id":"2525015392","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525015392","pubTimestamp":1744021599,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Shanghai Fosun Pharma Says Approval Received From NMPA For Clinical Trial Of CMC-2310 Oral Soluble FilmApril 7  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:RECEIVED APPROVAL FROM NMPA FOR THE CLINICAL TRIAL OF CMC-2310 ORAL SOLUBLE FILMFurther company coverage: 600196.SS ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0060":"抗癌","BK0196":"行业龙头","BK0187":"一线龙头","BK0028":"国家队","BK0175":"白马股","BK0239":"医药制造","BK0183":"MSCI概念","BK0188":"融资融券","BK0096":"民营医院","BK0012":"证金概念"},"translate_title":"简介-上海复星医药表示CMC-2310口服可溶性膜获NMPA批准临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9},"content_text":"BRIEF-Shanghai Fosun Pharma Says Approval Received From NMPA For Clinical Trial Of CMC-2310 Oral Soluble FilmApril 7 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:RECEIVED APPROVAL FROM NMPA FOR THE CLINICAL TRIAL OF CMC-2310 ORAL SOLUBLE FILMFurther company coverage: 600196.SS ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2525015392","isCrawlerRequest":true}